TERT promoter mutations were identified in 56% (1346/2411) bladder cancers, 43% (966/2243) melanomas, 39% (1403/3614) gliomas, 41% (395/959) thyroid cancers, and 23% (183/782) HNC (Fig. 1; Supplementary Table S2). This evidence concerns the gene TERT and thyroid cancer.